ImmuPharma PLC (LON: IMM), a specialist drug discovery and development company, has announced that, further to the announcement of 13th December 2019, that its shares will be admitted to trading on Euronext Growth Brussels under ticker ‘ALIMM’, it has today published the Information Note, as required by the Euronext Growth Market Rules Book and Belgian financial regulations.
The Information Note is available on ImmuPharma’s website www.immupharma.co.uk. Attention is drawn to certain financial information on a period subsequent to that notified in our Interim Results which is included in Parts II and IV of the Information Note which is notifiable under AIM Rule 11. This information is set out in the Appendix below.
Admission to Euronext is expected to take effect from 19 December 2019. This new listing does not affect the trading of ImmuPharma’s shares on AIM, nor is there any intention from the Company to raise additional funds from either AIM or Euronext.
The dual listing on Euronext Growth Brussels aims to further increase the visibility of ImmuPharma’s shares in continental Europe and with European investors, following the Company’s recent deal with Avion Pharmaceuticals, who are now funding an international Phase III trial for the lead programme, Lupuzor™. The investment thesis for ImmuPharma and specifically Lupuzor™ has been repositioned and the Company looks forward to providing further progress updates on the Phase III program with Avion, as well as entering into additional partnerships outside of the US.